Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130


S100A4 (metastasin) positive mesenchymal canine mammary tumour spheroids reduce Tenascin C synthesis under DMSO exposure in vitro.

Kau S, Miller I, Tichy A, Gabriel C.

Vet Comp Oncol. 2017 Dec;15(4):1428-1444. doi: 10.1111/vco.12287. Epub 2017 Jan 11.


Distinct neural correlates of attending speed vs. coherence of motion.

Kau S, Strumpf H, Merkel C, Stoppel CM, Heinze HJ, Hopf JM, Schoenfeld MA.

Neuroimage. 2013 Jan 1;64:299-307. doi: 10.1016/j.neuroimage.2012.08.080. Epub 2012 Sep 4.


Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.

Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN.

Oncologist. 2011;16(11):1527-34. doi: 10.1634/theoncologist.2011-0134. Epub 2011 Oct 31.


Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy.

Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, Kamal A, Hsu L, Hortobagyi GN, Sahin AA.

Cancer Invest. 2010 Jun;28(5):554-9. doi: 10.3109/07357900903286925.


Effects of chronic hepatitis C infection on the treatment of breast cancer patients.

Morrow PK, Tarrand JJ, Taylor SH, Kau SW, Theriault RL, Hortobagyi GN, Broglio KR, Hahn KM.

Ann Oncol. 2010 Jun;21(6):1233-6. doi: 10.1093/annonc/mdp458. Epub 2009 Oct 29.


Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM.

Ann Oncol. 2009 Dec;20(12):1953-8. doi: 10.1093/annonc/mdp263. Epub 2009 Jul 12.


Circulating tumor cells in metastatic inflammatory breast cancer.

Mego M, De Giorgi U, Hsu L, Ueno NT, Valero V, Jackson S, Andreopoulou E, Kau SW, Reuben JM, Cristofanilli M.

Ann Oncol. 2009 Nov;20(11):1824-8. doi: 10.1093/annonc/mdp207. Epub 2009 Jun 25.


Survival among women with triple receptor-negative breast cancer and brain metastases.

Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM.

Ann Oncol. 2009 Apr;20(4):621-7. doi: 10.1093/annonc/mdn682. Epub 2009 Jan 15.


Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.

Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM.

J Clin Oncol. 2009 Jan 10;27(2):220-6. doi: 10.1200/JCO.2008.17.9952. Epub 2008 Dec 1.


Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.

Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM.

J Clin Oncol. 2008 Sep 1;26(25):4072-7. doi: 10.1200/JCO.2007.14.4527.


Residual risk of breast cancer recurrence 5 years after adjuvant therapy.

Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ.

J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83. doi: 10.1093/jnci/djn233. Epub 2008 Aug 11.


Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger.

Eralp Y, Smith TL, Altundağ K, Kau SW, Litton J, Valero V, Buzdar A, Hortobagyi GN, Arun B.

J Cancer Res Clin Oncol. 2009 Jan;135(1):141-8. doi: 10.1007/s00432-008-0428-9. Epub 2008 Jun 26.


Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience.

Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y.

Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1096-103. doi: 10.1158/1055-9965.EPI-08-0201.


Prognostic value of body mass index in locally advanced breast cancer.

Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN, Cristofanilli M.

Clin Cancer Res. 2008 Mar 15;14(6):1718-25. doi: 10.1158/1078-0432.CCR-07-1479.


Defining prognosis for women with breast cancer and CNS metastases by HER2 status.

Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM.

Ann Oncol. 2008 Jul;19(7):1242-8. doi: 10.1093/annonc/mdn036. Epub 2008 Mar 11.


Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.

Er O, Frye DK, Kau SW, Broglio K, Valero V, Hortobagyi GN, Arun B.

Cancer J. 2008 Jan-Feb;14(1):62-8. doi: 10.1097/PPO.0b013e3181629a7b.


Prognostic significance of HER-2 status in women with inflammatory breast cancer.

Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM; Inflammatory Breast Cancer Research Group.

Cancer. 2008 May 1;112(9):1905-11. doi: 10.1002/cncr.23350.


Prognostic value of initial clinical disease stage after achieving pathological complete response.

Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobágyi GN, Gonzalez-Angulo AM.

Oncologist. 2008 Jan;13(1):6-15. doi: 10.1634/theoncologist.2007-0107.


Development of new cancers in patients with DCIS: the M.D. Anderson experience.

Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Yang W, Albarracin C, Meric F, Hortobagyi G, Theriault R.

Ann Surg Oncol. 2008 Jan;15(1):244-9. Epub 2007 Nov 28.


Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis.

Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E.

Cancer. 2007 Dec 15;110(12):2640-7.


Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.

Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN.

Cancer. 2007 Oct 1;110(7):1436-44.


Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.

Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, Buzdar AU.

Cancer. 2007 Sep 15;110(6):1195-200.


HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.

Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L.

Breast Cancer Res Treat. 2008 Mar;108(2):183-90. Epub 2007 Apr 28.


Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.

McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, Hortobagyi GN, Buchholz TA.

Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1004-9. Epub 2007 Apr 6.


Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.

Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V.

Clin Breast Cancer. 2007 Feb;7(6):471-9.


Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.

Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L.

Ann Oncol. 2007 May;18(5):874-80. Epub 2007 Feb 10.


Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma.

Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, Cristofanilli M.

Clin Breast Cancer. 2006 Dec;7(5):396-400.


Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?

Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB.

Breast Cancer Res Treat. 2007 May;102(3):347-56. Epub 2006 Sep 21.


Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM.

J Clin Oncol. 2006 Mar 1;24(7):1037-44.


Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.

Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, Valero V.

Cancer. 2006 Mar 1;106(5):1000-6.


Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.

Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V.

J Clin Oncol. 2005 Dec 20;23(36):9304-11.


Squamous cell carcinoma of the breast.

Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, Valero V, Hortobagyi GN.

J Clin Oncol. 2005 Nov 1;23(31):7827-35.


Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.

Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN.

J Clin Oncol. 2005 Oct 1;23(28):7098-104.


Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.

Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, Yin G, Kau SW, Hortobagyi GN, Rivera E.

Cancer. 2005 Sep 15;104(6):1158-71.


The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.

Montero AJ, Rouzier R, Lluch A, Theriault RL, Buzdar AU, Delaloge S, Bermejo B, Le M, Kau SW, Dunant A, Arriagada R, Spielmann M, Garcia-Conde J, Sahin AA, Singletary SE, Hortobagyi GN, Valero V.

Cancer. 2005 Jul 15;104(2):229-35.


Women age < or = 35 years with primary breast carcinoma: disease features at presentation.

Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B.

Cancer. 2005 Jun 15;103(12):2466-72.


Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma.

Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN.

Cancer. 2005 Mar 15;103(6):1122-8.


Breast cancer treatment guidelines in older women.

Giordano SH, Hortobagyi GN, Kau SW, Theriault RL, Bondy ML.

J Clin Oncol. 2005 Feb 1;23(4):783-91.


Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.

Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buchholz TA, Hortobagyi GN.

J Clin Oncol. 2005 Jan 1;23(1):41-8. Erratum in: J Clin Oncol. 2013 Aug 10;31(23):2977. Buccholz, Thomas A [corrected to Buchholz, Thomas A].


Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.

Yu TK, Whitman GJ, Thames HD, Buzdar AU, Strom EA, Perkins GH, Schechter NR, McNeese MD, Kau SW, Thomas ES, Hortobagyi GN, Buchholz TA.

J Natl Cancer Inst. 2004 Nov 17;96(22):1676-81.


p53 expression as a prognostic marker in inflammatory breast cancer.

Gonzalez-Angulo AM, Sneige N, Buzdar AU, Valero V, Kau SW, Broglio K, Yamamura Y, Hortobagyi GN, Cristofanilli M.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6215-21.


Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.

Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, Smith TL, Hortobagyi GN.

Cancer. 2004 Oct 15;101(8):1760-6.


Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma.

Resetkova E, Gonzalez-Angulo AM, Sneige N, Mcdonnell TJ, Buzdar AU, Kau SW, Yamamura Y, Reuben JM, Hortobagyi GN, Cristofanilli M.

Cancer. 2004 Sep 1;101(5):913-7.


Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer.

Pusztai L, Krishnamurti S, Perez Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC Jr, Hortobagyi GN.

Cancer Invest. 2004;22(2):248-56.


Aeromonas hydrophila orbital cellulitis in a patient with myelodysplastic syndrome.

Chou SY, Tsai CC, Kau SC, Kau HC, Hsu WM.

J Chin Med Assoc. 2004 Jan;67(1):51-3.


Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.

Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN.

Clin Breast Cancer. 2004 Feb;4(6):415-9.


Is breast cancer survival improving?

Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN.

Cancer. 2004 Jan 1;100(1):44-52.


Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.

Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L.

Cancer. 2003 Apr 1;97(7):1758-65.

Supplemental Content

Support Center